Sub Banner Image

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

Market Impact

Vandana Singh

·

July 25, 2025

·

Benzinga

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.